Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy
Radwan, I., Mohammad, H., Makary, S., Ameen, A., El-Kherbetawy, M., El-Sherbeeny, N. (2022). Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy. EKB Journal Management System, 25(3), 14-35. doi: 10.21608/scumj.2022.264870
Israa M. Radwan; Hala MF. Mohammad; Samy Makary; Angie M. Ameen; Mohammad K. El-Kherbetawy; Nagla A. El-Sherbeeny. "Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy". EKB Journal Management System, 25, 3, 2022, 14-35. doi: 10.21608/scumj.2022.264870
Radwan, I., Mohammad, H., Makary, S., Ameen, A., El-Kherbetawy, M., El-Sherbeeny, N. (2022). 'Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy', EKB Journal Management System, 25(3), pp. 14-35. doi: 10.21608/scumj.2022.264870
Radwan, I., Mohammad, H., Makary, S., Ameen, A., El-Kherbetawy, M., El-Sherbeeny, N. Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy. EKB Journal Management System, 2022; 25(3): 14-35. doi: 10.21608/scumj.2022.264870

Protective Effects of Telmisartan and Trimetazidine in Isoproterenol-Induced Myocardial Hypertrophy in Rats: Role of Autophagy

Suez Canal University Medical Journal
Article 2, Volume 25, Issue 3, October 2022, Page 14-35  XML PDF (1.37 MB)
Document Type: Original Article
DOI: 10.21608/scumj.2022.264870
View on SCiNiTO View on SCiNiTO
Authors
Israa M. Radwan email 1; Hala MF. Mohammadorcid 2; Samy Makary3; Angie M. Ameen3; Mohammad K. El-Kherbetawy4; Nagla A. El-Sherbeeny1
1Department of Clinical Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
2Department of Clinical Pharmacology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt+/ Central Laboratory, Center of Excellence in Molecular and Cellular Medicine (CEMCM), Faculty of Medicine, Suez Canal University, Ismailia, Egypt
3Department of Medical Physiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
4Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background: Myocardial hypertrophy, when pathological and sustained, is one of the predictors of cardiovascular morbidity. Telmisartan (TEL) and trimetazidine (TMZ) are drugs commonly used in cardiovascular diseases, including those leading to myocardial hypertrophy. It would be adventitious if their combination also protected against myocardial hypertrophy. Aim: This work compared the effect of TEL, TMZ, and their combination in preventing myocardial hypertrophy in rats.  Materials and Methods: 82 male albino rats were randomized into 10 groups. Groups included untreated, vehicle, TEL, and TMZ control groups. The other 6 groups received daily oral gavage for 35 days as follows: TEL (10 mg/kg), TMZ at two doses (10 & 20 mg/kg.), and two combination groups of TEL + TMZ (10 or 20 mg/kg). On days 29th -35th rats received IP ISP (4 mg/kg/day) for a week to induce myocardial hypertrophy. Results: TEL, TMZ (20mg/Kg), and their combination significantly protected against ISP-induced myocardial hypertrophy as denoted by decreased heart weight (HW), HW/body weight (BW) ratio, decreased left ventricular wall thickness, fibrosis area, TGF-β1, and β-MHC. Treated groups had improved ECG, better myocardial contractility, and significantly decreased autophagy markers; LC3-I, LC3-II, and LC3-II/LC3-I ratio than that of ISP group. Conclusion: TEL and TMZ have comparable favorable effects against experimental myocardial hypertrophy that involve inhibition of myocardial autophagy. Further experimental in vivo studies are needed to explore the effects of individual and combined therapeutic regimens on different key regulators of autophagy in ISP-induced myocardial hypertrophy.
Keywords
Keywords: Isoproterenol-Induced Myocardial hypertrophy; telmisartan; trimetazidine
Statistics
Article View: 528
PDF Download: 204